Cellesce Ltd
Cellesce has invented and patented a unique bioprocess for the expansion of human-derived, normal and cancer organoids for a multitude of applications including drug discovery and organ-on-a-chip applications. Until recently, organoids could only be grown and expanded manually. This is a technically challenging, time-consuming, and labour-intensive process resulting in small numbers of inconsistently sized organoids, limiting their suitability for use in high throughput applications and widespread use by big pharma and biotech. Cellesce’s patented ‘disruptive’ bioprocess, now in its second generation has enabled a significant increase in PDO production compared to manual processes.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2013
About Us
Cellesce was founded in 2013 and is built on biochemical and bioprocess engineering expertise from the University of Bath and cell and organoid biology expertise from Cardiff University. In December 2017 Cellesce moved into the Medicentre in Cardiff, Wales.
Furthermore, better process controls utilising in-line sensors and real-time monitoring ensure precise culture conditions, improved yield and control of organoid size and reduced batch to batch, user to user variability. A significant step-change to existing manual PDO culture methods, enabling organoids to enter the mainstream earlier in the drug discovery cascade.